about
Characterization of the MRP4- and MRP5-mediated transport of cyclic nucleotides from intact cellsCharacterization of the transport of nucleoside analog drugs by the human multidrug resistance proteins MRP4 and MRP5MicroRNAs in mesothelioma: from tumour suppressors and biomarkers to therapeutic targetsmiR-193a-3p is a potential tumor suppressor in malignant pleural mesotheliomaCloning of a human renal p-aminohippurate transporter, hROAT1Genomic structure and in vivo expression of the human organic anion transporter 1 (hOAT1) gene.The importance of RT-qPCR primer design for the detection of siRNA-mediated mRNA silencing.Haemolysis during sample preparation alters microRNA content of plasma.Mutational analysis of hedgehog signaling pathway genes in human malignant mesotheliomaLong non coding RNAs (lncRNAs) are dysregulated in Malignant Pleural Mesothelioma (MPM).Therapeutic and biological importance of getting nucleotides out of cells: a case for the ABC transporters, MRP4 and 5.Cilengitide inhibits attachment and invasion of malignant pleural mesothelioma cells through antagonism of integrins αvβ3 and αvβ5.Blockade of aquaporin 1 inhibits proliferation, motility, and metastatic potential of mesothelioma in vitro but not in an in vivo modelMiR-score: a novel 6-microRNA signature that predicts survival outcomes in patients with malignant pleural mesothelioma.The potential impact of drug transporters on nucleoside-analog-based antiviral chemotherapy.KCa1.1, a calcium-activated potassium channel subunit alpha 1, is targeted by miR-17-5p and modulates cell migration in malignant pleural mesothelioma.Fibulin-3 levels in malignant pleural mesothelioma are associated with prognosis but not diagnosis.MicroRNA-7 as a tumor suppressor and novel therapeutic for adrenocortical carcinomaA proteomics-based approach identifies secreted protein acidic and rich in cysteine as a prognostic biomarker in malignant pleural mesothelioma.YB-1, the E2F pathway, and regulation of tumor cell growth.MicroRNA gene expression signatures in long-surviving malignant pleural mesothelioma patients.An RNAi-based screen reveals PLK1, CDK1 and NDC80 as potential therapeutic targets in malignant pleural mesothelioma.Interactions of dietary phytochemicals with ABC transporters: possible implications for drug disposition and multidrug resistance in cancer.Circulating microRNAs: Association with disease and potential use as biomarkers.Molecular biomarkers in malignant mesothelioma: state of the art.Challenges and controversies in the diagnosis of mesothelioma: Part 1. Cytology-only diagnosis, biopsies, immunohistochemistry, discrimination between mesothelioma and reactive mesothelial hyperplasia, and biomarkers.Challenges and controversies in the diagnosis of malignant mesothelioma: Part 2. Malignant mesothelioma subtypes, pleural synovial sarcoma, molecular and prognostic aspects of mesothelioma, BAP1, aquaporin-1 and microRNA.The ABC transporter BCRP/ABCG2 is a placental survival factor, and its expression is reduced in idiopathic human fetal growth restriction.Interactions between hepatic Mrp4 and Sult2a as revealed by the constitutive androstane receptor and Mrp4 knockout mice.Validation of tissue microarray technology in malignant pleural mesothelioma.Tumor Suppressor microRNAs Contribute to the Regulation of PD-L1 Expression in Malignant Pleural Mesothelioma.Exploiting microRNAs As Cancer Therapeutics.Loss of miR-223 and JNK Signaling Contribute to Elevated Stathmin in Malignant Pleural Mesothelioma.Restoring expression of miR-16: a novel approach to therapy for malignant pleural mesothelioma.Modulatory effects of curcumin on multi-drug resistance-associated protein 5 in pancreatic cancer cells.The potency of siRNA-mediated growth inhibition following silencing of essential genes is dependent on siRNA design and varies with target sequence.Cell-free microRNAs: potential biomarkers in need of standardized reporting.The human multidrug resistance protein MRP5 transports folates and can mediate cellular resistance against antifolates.Evidence for two interacting ligand binding sites in human multidrug resistance protein 2 (ATP binding cassette C2).Characterization of drug transport by the human multidrug resistance protein 3 (ABCC3).
P50
Q28183236-8D0C050D-1AB2-46C2-9DFF-2ED554DB89E8Q28191103-1B0E8243-BC13-4973-A541-0C126BF9F739Q28396395-AD471F0A-C1DB-44E9-A297-9A70CDBEE0A2Q28397829-4937BB1A-E697-48CB-9BAB-0B49551FCF7DQ28610101-6AF5074C-259F-4CEC-B98D-D5A697139738Q30913041-5D61BE89-B6B0-43BF-93FA-37FF3C9E5610Q33911870-31336506-278D-4AB8-AA52-9F4EFEB10AE1Q34016595-D2B43ECF-1E9C-4147-8822-48E1CC1D2FFAQ34795828-D47110A5-1099-4E2A-A06C-AC6669B1901FQ34970431-3790F7AA-B533-4D91-9472-F526B0C387FDQ34983644-EC9801C4-7FB9-4865-8D64-7A4645596740Q35111316-B94B0AC7-5448-405D-B307-044BFD23F038Q35189370-FD105C34-B459-44B7-BCF6-D7DBF684B167Q35511541-0D5DFCED-3790-48C8-87A7-8EFDAB047B8CQ35693668-5F5A79A1-62F8-49A1-A1EA-2CB4767C90BDQ36035319-175A95DC-B002-422F-B0FA-616A2114CA72Q36081391-90C24354-D208-420D-9A92-4AC189A18B8AQ36546760-D1FDCD65-92E5-4E25-82EC-36C200358144Q36662001-6C5AA034-455F-4504-8BC5-5F94ADFFCE6CQ36755479-AE088FA2-DCF8-4F95-8763-92EC2933C674Q37049227-FDD16504-9F3B-4391-B646-1CF1CA4C0F1CQ37507415-7181EC3E-DCDF-4197-8B91-D7725750A545Q37740126-C94FAE8C-8DBD-481F-8185-83423244E228Q37818867-62B85662-00BF-4CAC-8013-FDFCEEB88F06Q37857610-62AA8E0D-2EF9-4B09-982E-F3BFD5C2F9C2Q38118298-570CFD72-1E6A-4D08-95FF-363D00688365Q38119922-49F3EFE0-83F0-4B4E-9FAB-5304A1A9C9DDQ38300490-F8A8C2DC-5FF0-4D13-8B03-A8AEBF62C746Q38343998-EF7C4CFE-FA1D-4388-BC3A-ED5452197D26Q38412580-3CF0591D-7431-4ADE-B62E-F48F89A155F2Q38718563-16C83928-D197-433F-AE01-4A3D856754D6Q38764098-58591776-E4E3-480D-B29F-823AD5826276Q38893024-6ADF18C5-2CCF-4AB3-AAB7-C7E8B28E8915Q39073648-006A97B6-B000-4BBF-9459-530B72B34248Q39626074-A57B4636-53F5-440F-8B04-7C2870B3A5A4Q39769941-71B69EDC-87FE-4F4E-A6EA-DE9E8CF9CED5Q39946127-A95771BB-332C-4D94-8B94-2310A496BF3EQ40421070-D7BD3318-05EF-440C-83BC-D3A7B6C4C1DCQ40654202-302DB9F1-946B-417F-BB98-FC9431D3B24EQ40777480-0136030E-8804-487D-854C-337E2B5D6216
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Glen Reid
@ast
Glen Reid
@en
Glen Reid
@es
Glen Reid
@nl
Glen Reid
@sl
type
label
Glen Reid
@ast
Glen Reid
@en
Glen Reid
@es
Glen Reid
@nl
Glen Reid
@sl
prefLabel
Glen Reid
@ast
Glen Reid
@en
Glen Reid
@es
Glen Reid
@nl
Glen Reid
@sl
P106
P1153
7402424771
P21
P2798
P31
P496
0000-0001-6465-5223